Summary
IDEXX Laboratories, Inc. reported robust financial performance for the first quarter of 2026, demonstrating significant revenue growth and improved profitability. Total revenue increased by 14.3% year-over-year to $1.14 billion, driven by strong demand across all operating segments, particularly within the Companion Animal Group (CAG). The company achieved a 15.9% increase in gross profit, expanding the gross profit margin by 100 basis points due to recurring revenue growth, operational efficiencies, and effective price realization, despite inflationary pressures. Net income saw a substantial rise of 14.8% to $278.4 million, translating to diluted earnings per share of $3.47, up from $2.96 in the prior year. The company's balance sheet remains solid with $200.5 million in cash and cash equivalents and $718.2 million in available borrowing capacity under its credit facility. Significant stock repurchase activity continued, reflecting a commitment to returning value to shareholders. The company provided a positive outlook, anticipating favorable currency impacts for the remainder of the year.
Financial Highlights
52 data points| Revenue | $1.14B |
| Cost of Revenue | $418.08M |
| Gross Profit | $722.74M |
| R&D Expenses | $65.79M |
| Operating Expenses | $360.15M |
| Operating Income | $362.59M |
| Net Income | $278.45M |
| EPS (Basic) | $3.50 |
| EPS (Diluted) | $3.47 |
| Shares Outstanding (Basic) | 79.65M |
| Shares Outstanding (Diluted) | 80.16M |
Key Highlights
- 1Total revenue increased by 14.3% to $1.14 billion, driven by broad-based growth across segments, especially CAG.
- 2Gross profit grew by 15.9% to $722.7 million, with a gross profit margin expansion of 100 basis points to 63.4%.
- 3Net income rose 14.8% to $278.4 million, with diluted EPS improving to $3.47 from $2.96 year-over-year.
- 4Strong performance in CAG Diagnostics recurring revenue, including VetLab consumables and reference laboratory services, with organic growth of 11.0% and 11.6% respectively.
- 5Cash flows from operations improved by $28.3 million to $266.2 million, demonstrating healthy operational cash generation.
- 6The company maintained a strong liquidity position with $200.5 million in cash and cash equivalents and significant availability under its credit facility.
- 7Continued aggressive share repurchase program, with $360.8 million spent on open market repurchases during the quarter.